Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Hertogs, K' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 50 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Miller, MD; Margot, NA; Hertogs, K; Larder, B; Miller, V
      Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples

      NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
    2. Weidle, PJ; Kityo, CM; Mugyenyi, P; Downing, R; Kebba, A; Pieniazek, D; Respess, R; Hertogs, K; De Vroey, V; Dehertogh, P; Bloor, S; Larder, B; Lackritz, E
      Resistance to antiretroviral therapy among patients in Uganda

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    3. Adje, C; Cheingsong, R; Roels, TH; Maurice, C; Djomand, G; Verbiest, W; Hertogs, K; Larder, B; Monga, B; Peeters, M; Eholie, S; Bissagene, E; Coulibaly, M; Respess, R; Wiktor, SZ; Chorba, T; Nkengasong, JN
      High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    4. Torti, C; Gilleece, Y; Hertogs, K; Gazzard, BG; Pozniak, AL
      R211K and L214F ho not invariably confer high level phenotypic resistance to thymidine analogs in zidovndine-naive patients with M184V

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    5. Briones, C; Perez-Olmeda, M; Rodriguez, C; del Romero, J; Hertogs, K; Soriano, V
      Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    6. Plettenberg, A; Albrecht, D; Lorenzen, T; Paech, V; Petersen, H; Fenner, T; Meyer, T; Arndt, R; Hertogs, K; Pauwels, R; Weitzel, T; Stoehr, A
      Resistance analyses in HIV infected patients with a history of multiple antiretroviral treatment regimens

      SEXUALLY TRANSMITTED INFECTIONS
    7. Vandamme, AM; Houyez, F; Banhegyi, D; Clotet, B; De Schrijver, G; De Smet, KAL; Hall, WW; Harrigan, R; Hellmann, N; Hertogs, K; Holtzer, C; Larder, B; Pillay, D; Race, E; Schmit, JC; Schuurman, R; Shulse, E; Sonnerborg, A; Miller, V
      Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up

      ANTIVIRAL THERAPY
    8. Caride, E; Hertogs, K; Larder, B; Dehertogh, P; Brindeiro, R; Machado, E; De Sa, CAM; Eyer-Silva, WA; Sion, FS; Passioni, LFC; Menezes, JA; Calazans, AR; Tanuri, A
      Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virustype 1 found in Brazilian patients failing HAART

      VIRUS GENES
    9. Dronda, F; Casado, JL; Moreno, S; Hertogs, K; Garcia-Arata, I; Antela, A; Perez-Elias, MJ; Ruiz, L; Larder, B
      Phenotypic cross-resistance to nelfinavir: The role of prior antiretroviral therapy and the number of mutations in the protease gene

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    10. Casado, JL; Dronda, F; Hertogs, K; Sabido, R; Antela, A; Marti-Belda, P; Dehertogh, P; Moreno, S
      Efficacy, tolerance, and pharmacokinetics of the combination of stavudine,nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    11. Ross, L; Liao, QM; Gao, HT; Pham, S; Tolson, J; Hertogs, K; Larder, B; Saag, MS
      Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    12. Torti, C; Pozniak, A; Nelson, M; Hertogs, K; Gazzard, BG
      Distribution of K103N and/or Y181CHIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors

      Journal of antimicrobial chemotherapy
    13. Verbiest, W; Brown, S; Cohen, C; Conant, M; Henry, K; Hunt, S; Sension, M; Stein, A; Stryker, R; Thompson, M; Schel, P; Van Den Broeck, R; Bloor, S; Alcorn, T; Van Houtte, M; Larder, B; Hertogs, K
      Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study

      AIDS
    14. Miller, V; Vandamme, AM; Loveday, C; Staszewski, S; Lundgren, J; Youle, M; Ait-Khaled, M; Boucher, C; Brun-Vezinet, F; Dedes, N; Giaquinto, C; Hertogs, K; Houyez, F; Perrin, L; Pillay, D; Schmit, JC; Schuurman, R; Lange, J; Banhegyi, D; Biondi, G; Broekhuizen, A; Bush-Donovan, C; Camacho, R; Carlier, H; Clavel, F; Clotet, B; Clumeck, N; Colebunders, R; De Clerq, K; De Jaegher, JJ; De Schrijver, G; De Smet, K; Hall, W; Harrigan, R; Hatzakis, A; Hellmann, N; Hoetelmans, R; Holtzer, C; Katlama, C; Larder, D; Loriaux, E; McCreedy, B; Mulcahy, F; Opravil, M; Phillips, A; Ruiz, N; Shulse, E; Sonnerborg, A; Soriano, V; Steel, H; Vella, S; Williams, A
      Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting

      AIDS
    15. Shafer, RW; Hertogs, K; Zolopa, AR; Warford, A; Bloor, S; Betts, BJ; Merigan, TC; Harrigan, R; Larder, BA
      High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samplesfrom heavily treated patients

      JOURNAL OF CLINICAL MICROBIOLOGY
    16. Lennerstrand, J; Hertogs, K; Stammers, DK; Larder, BA
      Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type1 mutants

      JOURNAL OF VIROLOGY
    17. Bacheler, L; Jeffrey, S; Hanna, G; D'Aquila, R; Wallace, L; Logue, K; Cordova, B; Hertogs, K; Larder, B; Buckery, R; Baker, D; Gallagher, K; Scarnati, H; Tritch, R; Rizzo, C
      Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

      JOURNAL OF VIROLOGY
    18. Poles, MA; Elliott, J; Vingerhoets, J; Michiels, L; Scholliers, A; Bloor, S; Larder, B; Hertogs, K; Anton, PA
      Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma

      JOURNAL OF INFECTIOUS DISEASES
    19. Miller, V; Cozzi-Lepri, A; Hertogs, K; Gute, P; Larder, B; Bloor, S; Klauke, S; Rabenau, H; Phillips, A; Staszewski, S
      HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort

      ANTIVIRAL THERAPY
    20. De Meyer, S; Gong, ZJ; Hertogs, K; Depla, E; van Pelt, JF; Roskams, T; Maertens, G; Yap, SH
      Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on invitro hepatitis B virus infection

      JOURNAL OF VIRAL HEPATITIS
    21. Hertogs, K; Bloor, S; Kemp, SD; Van den Eynde, C; Alcorn, TM; Pauwels, R; Van Houtte, M; Staszewski, S; Miller, V; Larder, BA
      Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples

      AIDS
    22. Wegner, SA; Brodine, SK; Mascola, JR; Tasker, SA; Shaffer, RA; Starkey, MJ; Barile, A; Martin, GJ; Aronson, N; Emmons, WW; Stephan, K; Bloor, S; Vingerhoets, J; Hertogs, K; Larder, B
      Prevalence of genotypic and phenotypic resistance to anti-retroviral drugsin a cohort of therapy-naive HIV-1 infected US military personnel

      AIDS
    23. Casado, JL; Dronda, F; Hertogs, K; Antela, A; Moreno, S
      Failure of a ritonavir plus saquinavir-based rescue regimen precludes the use of protease inhibitors

      AIDS
    24. Casado, JL; Hertogs, K; Ruiz, L; Dronda, F; Van Cauwenberge, A; Arno, A; Garcia-Arata, I; Bloor, S; Bonjoch, A; Blazquez, J; Clotet, B; Larder, B
      Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen

      AIDS
    25. Miller, V; Sabin, C; Hertogs, K; Bloor, S; Martinez-Picado, J; D'Aquila, R; Larder, B; Lutz, T; Gute, P; Weidmann, E; Rabenau, H; Phillips, A; Staszewski, S
      Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

      AIDS
    26. Larder, BA; Hertogs, K; Bloor, S; van den Eynde, C; DeCian, W; Wang, YY; Freimuth, WW; Tarpley, G
      Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

      AIDS
    27. Hertogs, K; Bloor, S; De Vroey, V; Van den Eynde, C; Dehertogh, P; Van Cauwenberge, A; Sturmer, M; Alcorn, T; Wegner, S; Van Houtte, M; Miller, V; Larder, BA
      A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    28. Caride, E; Brindeiro, R; Hertogs, K; Larder, B; Dehertogh, P; Machado, E; de Sa, CAM; Eyer-Silva, WA; Sion, FS; Passioni, LFC; Menezes, JA; Calazans, AR; Tanuri, A
      Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART

      VIROLOGY
    29. Dybul, M; Chun, TW; Ward, DJ; Hertogs, K; Larder, B; Fox, CH; Orenstein, JM; Baird, BF; Li, YX; Green, LG; Engel, D; Liu, SY; Mican, JM; Fauci, AS
      Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor-sparing highly active antiretroviral therapy

      JOURNAL OF INFECTIOUS DISEASES
    30. Lepri, AC; Sabin, CA; Staszewski, S; Hertogs, K; Muller, A; Rabenau, H; Philips, AN; Miller, V
      Resistance profiles in patients with viral rebound on potent antiretroviral therapy

      JOURNAL OF INFECTIOUS DISEASES
    31. de Bethune, MP; Hertogs, K
      RT-PCR for amplification of specific fragments of HIV-1 genome

      ANTIVIRAL METHODS AND PROTOCOLS
    32. Gong, ZJ; De Meyer, S; van Pelt, J; Hertogs, K; Depla, E; Soumillion, A; Fevery, J; Yap, SH
      Transfection of a rat hepatoma cell line with a construct expressing humanliver annexin V confers susceptibility to hepatitis B virus infection

      HEPATOLOGY
    33. Harrigan, PR; Hertogs, K; Verbiest, W; Pauwels, R; Larder, B; Kemp, S; Bloor, S; Yip, B; Hogg, R; Alexander, C; Montaner, JSG
      Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting

      AIDS
    34. Larder, BA; Bloor, S; Kemp, SD; Hertogs, K; Desmet, RL; Miller, V; Sturmer, M; Staszewski, S; Ren, J; Stammers, DK; Stuart, DI; Pauwels, R
      A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    35. DEMEYER S; GONG ZJ; HERTOGS K; DEPLA E; MAERTENS G; YAP SH
      CHARACTERIZATION OF SMALL HEPATITIS-B SURFACE-ANTIGEN EPITOPES FOR BINDING TO HUMAN ANNEXIN-V AND TO ANTI-HBSAG ANTIBODIES CAPABLE OF BLOCKING HEPATITIS-B VIRUS-INFECTION IN-VITRO

      Hepatology
    36. MILLER V; STURMER M; STASZEWSKI S; GROSCHEL B; HERTOGS K; DEBETHUNE MP; PAUWELS R; HARRIGAN PR; BLOOR S; KEMP SD; LARDER BA
      THE M184V MUTATION IN HIV-1 REVERSE-TRANSCRIPTASE (RT) CONFERRING LAMIVUDINE RESISTANCE DOES NOT RESULT IN BROAD CROSS-RESISTANCE TO NUCLEOSIDE ANALOG RT INHIBITORS

      AIDS
    37. HERTOGS K; DEBETHUNE MP; MILLER V; IVENS T; SCHEL P; VANCAUWENBERGE A; VANDENEYNDE C; VANGERWEN V; AZIJN H; VANHOUTTE M; PEETERS F; STASZEWSKI S; CONANT M; BLOOR S; KEMP S; LARDER B; PAUWELS R
      A RAPID METHOD FOR SIMULTANEOUS DETECTION OF PHENOTYPIC RESISTANCE TOINHIBITORS OF PROTEASE AND REVERSE-TRANSCRIPTASE IN RECOMBINANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES FROM PATIENTS TREATED WITH ANTIRETROVIRAL DRUGS

      Antimicrobial agents and chemotherapy
    38. Miller, V; de Bethune, RP; Kober, A; Sturmer, M; Hertogs, K; Pauwels, R; Stoffels, P; Staszewski, S
      Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    39. MILLER V; PHILLIPS A; ROTTMANN C; STASZEWSKI S; PAUWELS R; HERTOGS K; DEBETHUNE MP; KEMP SD; BLOOR S; HARRIGAN PR; LARDER BA
      DUAL RESISTANCE TO ZIDOVUDINE AND LAMIVUDINE IN PATIENTS TREATED WITHZIDOVUDINE-LAMIVUDINE COMBINATION THERAPY - ASSOCIATION WITH THERAPY FAILURE

      The Journal of infectious diseases
    40. GONG ZJ; DEMEYER S; VANPELT JF; HERTOGS K; SOUMILLION A; FEVERY J; YAP SH
      HUMAN ANNEXIN-V IS THE DETERMINING FACTOR FOR CELL INFECTABILITY BY HEPATITIS-B VIRUS

      Hepatology
    41. DEBETHUNE MP; AZIJN H; HERTOGS K; ANDRIES K; JANSSEN PAJ; PAUWELS R
      8-CHLORO-TIBO (R091767) AND AZT IN COMBINATION CAN PREVENT THE APPEARANCE OF RESISTANT HIV IN-VITRO

      Journal of acquired immune deficiency syndromes and human retrovirology
    42. MOEREMANS M; DERAEYMAEKER M; VANDENBROECK R; STOFFELS P; DEBRABANDER M; DECREE J; HERTOGS K; PAUWELS R; STASZEWSKI S; ANDRIES K
      VIROLOGICAL ANALYSIS OF HIV-1 ISOLATES IN PATIENTS TREATED WITH THE NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR R091767, )IMIDAZO[4,5,1-JK][1,4]BENZODIAZEPINE-2(1H)-THIONE MONOHYDROCHLORIDE (8-CHLORO-TIBO)

      Journal of acquired immune deficiency syndromes and human retrovirology
    43. AZIJN H; DEBETHUNE MP; HERTOGS K; ANDRIES K; JANSSEN PAJ; PAUWELS R
      DESIGN OF AN EXPERIMENTAL ASSAY THAT MIGHT BE OF PROGNOSTIC VALUE FORANTI-HIV COMBINATION THERAPY

      Journal of acquired immune deficiency syndromes and human retrovirology
    44. DEBRUIN WCC; HERTOGS K; LEENDERS WPJ; DEPLA E; YAP SH
      HEPATITIS-B VIRUS - SPECIFIC BINDING AND INTERNALIZATION OF SMALL HBSAG BY HUMAN HEPATOCYTES

      Journal of General Virology
    45. HERTOGS K; DEPLA E; CRABBE T; DEBRUIN W; LEENDERS W; MOSHAGE H; YAP SH
      SPONTANEOUS DEVELOPMENT OF ANTI-HEPATITIS-B VIRUS ENVELOPE (ANTIIDIOTYPIC) ANTIBODIES IN ANIMALS IMMUNIZED WITH HUMAN LIVER ENDONEXIN-II ORWITH THE F(AB')(2) FRAGMENT OF ANTI-HUMAN LIVER ENDONEXIN-II IMMUNOGLOBULIN-G - EVIDENCE FOR A RECEPTOR-LIGAND-LIKE RELATIONSHIP BETWEEN SMALL HEPATITIS-B SURFACE-ANTIGEN AND ENDONEXIN-II

      Journal of virology
    46. DEBRUIN W; LEENDERS W; KOS T; HERTOGS K; YAP SH
      THE HBSAG OF THE HEPATITIS-DELTA VIRUS (HDV) ENVELOPE ENABLES THE HDVTO INTERACT WITH ENDONEXIN-II, A SPECIFIC HBSAG BINDING-PROTEIN

      Hepatology
    47. HERTOGS K; LEENDERS W; DEBRUIN W; DEPLA E; MEHEUS L; RAYMACKERS J; MOSHAGE H; YAP SH
      HUMAN LIVER PLASMA-MEMBRANE ENDONEXIN-II IS A SPECIFIC BINDING-PROTEIN OF HEPATITIS-B VIRUS (HBV) ENVELOPE PROTEIN (HBSAG)

      Hepatology
    48. HERTOGS K; DEPLA E; DEBRUIN W; LEENDERS W; MOSHAGE H; YAP SH
      SPONTANEOUS DEVELOPMENT OF ANTI-HBS (ANTIIDIOTYPIC) ANTIBODIES IN RABBITS IMMUNIZED WITH HUMAN LIVER ENDONEXIN-II AND IN CHICKEN IMMUNIZED WITH FAB FRAGMENT OF RABBIT ANTI-HUMAN LIVER E-II IGG - EVIDENCES FOR A RECEPTOR-LIGAND RELATIONSHIP BETWEEN HBSAG AND ENDONEXIN-II

      Hepatology
    49. HERTOGS K; LEENDERS W; DEBRUIN W; DEPLA E; SABLON E; MOSHAGE H; YAP SH
      RECOMBINANT AND NATIVE HUMAN LIVER ENDONEXIN-II DO NOT DIFFER IN THEIR RECEPTOR-LIGAND INTERACTION WITH HEPATITIS-B VIRUS ENVELOPE PROTEIN

      Hepatology
    50. HERTOGS K; LEENDERS WPJ; DEPLA E; DEBRUIN WCC; MEHEUS L; RAYMACKERS J; MOSHAGE H; YAP SH
      ENDONEXIN-II, PRESENT ON HUMAN LIVER PLASMA-MEMBRANES, IS A SPECIFIC BINDING-PROTEIN OF SMALL HEPATITIS-B VIRUS (HBV) ENVELOPE PROTEIN

      Virology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/02/20 alle ore 02:44:47